stock · yahoo

Eisai Co., Ltd.

4523.T

$24.67
0.1 (-0.42%)
polled · warming up

Aşağıda Eisai Co., Ltd. (4523.T) için canlı hisse fiyatı, 1 yıllık grafik, 8 indikatör (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Hacim) ve karşılaştırma modu var. Portföyüne ekleyebilir, izleme listene yıldız atabilir veya fiyat alarmı kurabilirsin.

Day
-0.42%
-16.00
Week
-4.64%
-185.00
Month
-18.96%
-889.00
Year
-5.05%
-202.00
Prev close
$24.77
Volume
$3.78K
Market cap
$6.96B
Currency
USD (native JPY)

Financials

52w high
¥5,349
52w low
¥3,719
52w change
-6.05%
Day high
¥3,856
Day low
¥3,790
P/E (TTM)
27.74
Forward P/E
18.75
PEG
26.43
Price / Book
1.19
Beta (5Y)
-0.11
Enterprise value
1.04T
EV / Revenue
1.26
EV / EBITDA
11.28
EPS (TTM)
¥136.96
Forward EPS
¥202.57
Dividend yield
4.19%
Dividend rate
¥160
Payout ratio
116.98%
Revenue (TTM)
825.38B
EBITDA
92.42B
Free cash flow
-21.68B
Total cash
245.42B
Total debt
186.08B
Debt / Equity
20.11
Current ratio
2.24
Quick ratio
1.39
Profit margin
4.67%
Gross margin
76.83%
Return on assets
2.33%
Return on equity
4.53%
Shares outstanding
282.11M
Float
281.16M
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericHQ: Japanwww.eisai.co.jp

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in India. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Analyst & Risk

Consensus
Buy
Mean rating2.46 / 5
Analysts13
Next earnings2026-08-03
Buy 4Hold 8Strong sell 1
Analyst price target
¥4,715.39
Mean target · 13 analysts
+24.1%
upside
Low ¥3,500Now ¥3,799High ¥5,600
Beta (vs S&P 500)
-0.11
very stable
52-week change
-6.05%
Debt / Equity
20.11
very high leverage
Current ratio
2.24
Quick ratio
1.39
ROE
4.53%
ROA
2.33%
PEG ratio
26.43
richly valued
EV / Revenue
1.26
EV / EBITDA
11.28
Revenue growth
9.10%
EBITDA
92.42B
Free cash flow
-21.68B
Total cash
245.42B
Total debt
186.08B
Insider holdings
6.00%
Institutional
56.04%

Canlı tartışma

Giriş to join the discussion.

  • Henüz yorum yok. İlk siz olun.